G1T 38

Drug Profile

G1T 38

Alternative Names: G1T-38

Latest Information Update: 16 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator G1 Therapeutics
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Cyclin-dependent kinase 4 inhibitors; Cyclin-dependent kinase 6 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Breast cancer; Non-small cell lung cancer
  • Phase I Cancer

Most Recent Events

  • 29 Mar 2018 Phase-I/II clinical trials in Non-small cell lung cancer (Combination therapy, Metastatic disease) in USA (PO) (NCT03455829) (EudraCT2017-004315-39)
  • 21 Feb 2018 US FDA approves IND application for phase Ib/II to evaluate G1T 38 in combination with osimertinib (Tagrisso®) for the treatment of Non-small cell lung cancer prior to December 2017
  • 04 Jan 2018 G1 Therapeutics and GeneCentric Therapeutics enter into a research collaboration to identify G1T 38 response biomarkers for Non-small cell lung cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top